The U.S. Court of Appeals for the Federal Circuit has upheld a district court decision that Natera Inc. is entitled to an injunction of a Neogenomics Inc. assay for detection of circulating tumor DNA (ctDNA). This outcome serves as a sobering reminder that injunction can be obtained at the preliminary injunction stage by demonstrating that an effort to prove infringement is likely to succeed even in the absence of a thorough evaluation of the contested claims in that patent.
The first patenting from Los Angeles-based Ecate LLC sees the company’s founder, Allesandro Maggi, describe a bi-directional, closed-loop spinal cord machine interface that can bridge the gap in communication between the brain and the body in paralyzed patients.
University of Copenhagen has described cyclic peptides acting as postsynaptic density-95 (PSD-95) protein inhibitors reported to be useful for the treatment of neuropathic pain.
Scinnohub Pharmaceutical Co. Ltd. has divulged cyclin-dependent kinase (CDK) inhibitors, particularly CDK9 inhibitors, reported to be useful for the treatment of cancer.
Scientists at Helmholtz Zentrum fur Infektionsforschung GmbH and Lead Discovery Center GmbH have identified α-hemolysin (Staphylococcus aureus) inhibitors reported to be useful for the treatment of staphylococcal pneumonia.
Scientists at Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have synthesized kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Haisco Pharmaceutical Group Co. Ltd. has disclosed integrin αvβ1 and/or integrin αvβ6 antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
A bipartisan bill aimed at limiting patent thickets on biologics moved a step closer to law July 11 when the Senate passed it with unanimous consent in an unexpected vote that came more than one-and-a-half years after the Judiciary Committee reported it favorably to the Senate floor. The Affordable Prescriptions for Patients Act, S. 150, which would limit the type and number of patents that can be litigated under the Biologics Price Competition and Innovation Act (BPCIA), now awaits House action.
Korea Institute of Science and Technology has described diosgenin derivatives reported to be useful for the treatment of depression, multiple sclerosis, ischemic stroke, schizophrenia, amyotrophic lateral sclerosis, neuroblastoma, Alzheimer’s disease and post-traumatic stress disorders.
RSS
